(Q38534163)

3 September 2017

1 reference

title

Entinostat (SNDX-275) for the treatment of non-small cell lung cancer (English)

1 reference

3 September 2017

1 reference

ChEBI release 2020-05-28

1 reference

1

0 references

author name string

Luis E Raez

series ordinal

2

1 reference

PubMed ID

26098363

3 September 2017

Christian Rolfo

series ordinal

3

1 reference

PubMed ID

26098363

3 September 2017

language of work or name

English

0 references

publication date

22 June 2015

1 reference

Expert Opinion on Investigational Drugs

3 September 2017

1 reference

3 September 2017

24

1 reference

3 September 2017

8

1 reference

3 September 2017

1101-1109

1 reference

3 September 2017

Cancer statistics, 2014

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1056779

21 January 2018

Global cancer statistics

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1056779

Analysis of stage and clinical/prognostic factors for lung cancer from SEER registries: AJCC staging and collaborative stage data collection system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1056779

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1056779

Hallmarks of Cancer: The Next Generation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1056779

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1056779

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1056779

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1056779

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1056779

Epigenetics of lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1056779

The history of cancer epigenetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1056779

Targeting the epigenome for treatment of cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1056779

The language of covalent histone modifications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1056779

Enhanced histone acetylation and transcription: a dynamic perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1056779

Histone deacetylase inhibitors: molecular mechanisms of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1056779

Regulation of chromatin by histone modifications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1056779

Histone deacetylases and cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1056779

Histone Deacetylase Inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1056779

Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1056779

Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1056779

Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1056779

Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1056779

A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1056779

Interspecies differences in plasma protein binding of MS-275, a novel histone deacetylase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1056779

Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1056779

A phase I and pharmacokinetic study of the oral histone deacetylase inhibitor, MS-275, in patients with refractory solid tumors and lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1056779

Entinostat for treatment of solid tumors and hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1056779

Histone deacetylase inhibitor, MS-275, exhibits poor brain penetration: PK studies of [C]MS-275 using Positron Emission Tomography

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1056779

Factors affecting the pharmacokinetic profile of MS-275, a novel histone deacetylase inhibitor, in patients with cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1056779

MS-275, a potent orally available inhibitor of histone deacetylases--the development of an anticancer agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1056779

The histone deacetylase inhibitor MS-275 induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1056779

Combination therapy with vidaza and entinostat suppresses tumor growth and reprograms the epigenome in an orthotopic lung cancer model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1056779

HDAC inhibition synergistically enhances alkylator-induced DNA damage responses and apoptosis in multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1056779

Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1056779

Randomized phase II trial of erlotinib with and without entinostat in patients with advanced non-small-cell lung cancer who progressed on prior chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1056779

Anticancer activities of histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1056779

Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1056779

SGI-110 and entinostat therapy reduces lung tumor burden and reprograms the epigenome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1056779

Evaluation of azacitidine and entinostat as sensitization agents to cytotoxic chemotherapy in preclinical models of non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1056779

Epithelial-mesenchymal transitions in development and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1056779

Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1056779

Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1056779

Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1056779

Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1056779

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1056779

Erlotinib in previously treated non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1056779

DNA methylation markers and early recurrence in stage I lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1056779

Toxicological and metabolic considerations for histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1056779

Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1056779

10.1517/13543784.2015.1056779

21 January 2018

Identifiers

DOI

1 reference

3 September 2017

1 reference

PubMed ID

26098363